Small-molecule inhibitors targeting components of the Ras-ERK signaling have been clinically tested for the treatment of KRAS and BRAF mutated colorectal cancer; however, these inhibitors tend to acquire resistance and lead to bypass activation of Ras-ERK signaling, resulting in ineffective clinical outcomes (91). This evidence concerns the gene KRAS and colorectal cancer.